We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The start of a new wave: Developments in proteasome inhibition in multiple myeloma.
- Authors
Kwee Yong; Gonzalez-McQuire, Sebastian; Szabo, Zsolt; Schoen, Paul; Hajek, Roman
- Abstract
Multiple myeloma (MM) accounts for 10% of hematological cancers. Stem cell transplantation remains the cornerstone of first- I ine treatment for eligible patients, but historically, pharmaceutical treatment options for MM have been limited. The proteasome was identified as a target for MM therapy in the early 2000s and, in 2004, the boronic acid proteasome inhibitor bortezomib gained European approval. Bortezomib now plays a major role in MM treatment, but the duration of its use can be limited by toxicities such as peripheral neuropathy and the development of resistance. A new generation of proteasome inhibitors has since entered the treatment landscape: carfilzomib, an epoxyketone-based agent with a distinct mode of action, high clinical efficacy, and lower levels of peripheral neuropathy compared with bortezomib, received approval in 2015 for use in patients with relapsed and/or refractory MM (RRMM). Ixazomib, a second-generation, orally administered, boronic acid proteasome inhibitor, has also been approved for use in patients with RRMM. In just over a decade, proteasome inhibitor-based regimens have become an integral component of MM treatment; with more proteasome inhibitors in development, this remains a vibrant research area with potential to improve the lives of patients with MM in the years to come.
- Subjects
PROTEASOME inhibitors; MULTIPLE myeloma; STEM cell transplantation; BORONIC acids; PERIPHERAL neuropathy; PATIENTS
- Publication
European Journal of Haematology, 2018, Vol 101, Issue 2, p220
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13071